-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 29, Yahong Pharmaceuticals announced that it had been approved by Australian regulators to conduct Phase I clinical trials in its research product APL-1501.
the trial was designed to evaluate the safety, toerability and pharmacodynamic characteristics of the APL-1501.
APL-1501 will support the new international clinical development as the second generation of APL-1202 as the second generation of APL-1202 oral slow-release products developed by Yahong Pharmaceuticals through its improved New Drug Research and Development Technology Platform (PADD).
APL-1501 retains APL-1202 unique oral administration method, through the design of pre-drug molecules to improve its drug-forming, and on this basis supplemented by slow release technology, delay drug release, prolong drug plasma exposure time, can reduce the frequency of patients, thereby improving compliance.
the product has better drug characteristics, in addition to bladder cancer treatment, will be expected to enter more areas of treatment for clinical development, such as prostate cancer, urethra infections and so on.
addition, APL-1501, as a product independently developed by Yahong Pharmaceuticals, has carried out a global independent intellectual property layout, providing strong support for extending the product life cycle, expanding the international market and cooperation.
APL-1202 is a research product for the treatment of non-layer immersion bladder cancer, is the first oral, reversible methionine amino peptidease TYPE II (MetAP2) inhibitor to enter Phase III clinical studies in the world, and its Phase III registered clinical study in China has completed all subjects in 2019 and has completed Phase I clinical trials in the United States.
current standard treatment for non-muscle immersive bladder cancer is through urethra bladder tumor removal.
because of the high recurrence rate of tumors after surgery, bladder perfusion chemotherapy drugs or carcass immunotherapy are required.
options for second-line treatment in patients with relapses are very limited, and the standard treatment for high-risk patients with failed perfusions is a complete removal of the bladder.
has not yet been approved for the treatment of non-muscle immersive bladder cancer.
